have introduced an innovative prognostic scoring system dubbed “CRAFITY,” anchored in serum CRP and AFP levels, specifically tailored to prognosticate outcomes in HCC patients treated with atezolizumab plus bevacizumab.14 Here, CRP is linked to hepatocellular carcinoma.